Fibroblast subtypes in pancreatic cancer and pancreatitis: from mechanisms to therapeutic strategies.

IF 4.9 2区医学 Q2 CELL BIOLOGY Cellular Oncology Pub Date : 2024-04-01 Epub Date: 2023-09-18 DOI:10.1007/s13402-023-00874-x

Huizhen Huang, Wanyi Lu, Xiuli Zhang, Jiachun Pan, Feng Cao, Li Wen

{"title":"Fibroblast subtypes in pancreatic cancer and pancreatitis: from mechanisms to therapeutic strategies.","authors":"Huizhen Huang, Wanyi Lu, Xiuli Zhang, Jiachun Pan, Feng Cao, Li Wen","doi":"10.1007/s13402-023-00874-x","DOIUrl":null,"url":null,"abstract":"<p><p>Excessive fibrosis is a predominant feature of pancreatic stroma and plays a crucial role in the development and progression of pancreatic ductal adenocarcinoma (PDAC) and chronic pancreatitis (CP). Emerging evidence showed diversity and heterogeneity of fibroblasts play crucial and somewhat contradictory roles, the interactions between fibroblasts and pancreatic cells or infiltrating immune cells are of great importance during PDAC and CP progression, with some promising therapeutic strategies being tested. Therefore, in this review, we describe the classification of fibroblasts and their functions in PDAC and pancreatitis, the mechanisms by which fibroblasts mediate the development and progression of PDAC and CP through direct or indirect interaction between fibroblast and pancreatic parenchymal cells, or by remodeling the pancreatic immune microenvironment mediates the development and progression of PDAC and CP. Finally, we summarized the current therapeutic strategies and agents that directly target subtypes of fibroblasts or interfere with their essential functions.</p>","PeriodicalId":49223,"journal":{"name":"Cellular Oncology","volume":" ","pages":"383-396"},"PeriodicalIF":4.9000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cellular Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s13402-023-00874-x","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/9/18 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CELL BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Excessive fibrosis is a predominant feature of pancreatic stroma and plays a crucial role in the development and progression of pancreatic ductal adenocarcinoma (PDAC) and chronic pancreatitis (CP). Emerging evidence showed diversity and heterogeneity of fibroblasts play crucial and somewhat contradictory roles, the interactions between fibroblasts and pancreatic cells or infiltrating immune cells are of great importance during PDAC and CP progression, with some promising therapeutic strategies being tested. Therefore, in this review, we describe the classification of fibroblasts and their functions in PDAC and pancreatitis, the mechanisms by which fibroblasts mediate the development and progression of PDAC and CP through direct or indirect interaction between fibroblast and pancreatic parenchymal cells, or by remodeling the pancreatic immune microenvironment mediates the development and progression of PDAC and CP. Finally, we summarized the current therapeutic strategies and agents that directly target subtypes of fibroblasts or interfere with their essential functions.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

胰腺癌和胰腺炎中的成纤维细胞亚型：从机制到治疗策略。

过度纤维化是胰腺基质的主要特征，在胰腺导管腺癌（PDAC）和慢性胰腺炎（CP）的发生和发展过程中起着至关重要的作用。新的证据表明，成纤维细胞的多样性和异质性发挥着至关重要且有些矛盾的作用，成纤维细胞与胰腺细胞或浸润免疫细胞之间的相互作用在 PDAC 和 CP 的进展过程中具有重要意义，一些有前景的治疗策略正在接受测试。因此，在这篇综述中，我们描述了成纤维细胞的分类及其在 PDAC 和胰腺炎中的功能，成纤维细胞通过成纤维细胞和胰腺实质细胞之间的直接或间接相互作用，或通过重塑胰腺免疫微环境介导 PDAC 和 CP 的发生和发展的机制。最后，我们总结了目前直接针对成纤维细胞亚型或干扰其基本功能的治疗策略和药物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Cellular Oncology ONCOLOGY-CELL BIOLOGY

CiteScore

10.30

自引率

1.50%

发文量

审稿时长

12 months

期刊介绍： The Official Journal of the International Society for Cellular Oncology Focuses on translational research Addresses the conversion of cell biology to clinical applications Cellular Oncology publishes scientific contributions from various biomedical and clinical disciplines involved in basic and translational cancer research on the cell and tissue level, technical and bioinformatics developments in this area, and clinical applications. This includes a variety of fields like genome technology, micro-arrays and other high-throughput techniques, genomic instability, SNP, DNA methylation, signaling pathways, DNA organization, (sub)microscopic imaging, proteomics, bioinformatics, functional effects of genomics, drug design and development, molecular diagnostics and targeted cancer therapies, genotype-phenotype interactions. A major goal is to translate the latest developments in these fields from the research laboratory into routine patient management. To this end Cellular Oncology forms a platform of scientific information exchange between molecular biologists and geneticists, technical developers, pathologists, (medical) oncologists and other clinicians involved in the management of cancer patients. In vitro studies are preferentially supported by validations in tumor tissue with clinicopathological associations.